Tuberc Respir Dis.  2009 Jan;66(1):20-26.

Association between Bone Marrow Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer

• Seol HY
• Mok JH
• Yoon SH
• Kim JE
• Kim KU
• Park HK
• Kim SJ
• Kim YS
• Kim MK
• Park SK

Abstract

BACKGROUND
(18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for the diagnosis and staging of non-small cell lung cancer (NSCLC). The aim of this study is to determine whether the bone marrow hypermetabolism seen on FDG-PET predicts a response to chemotherapy in patients with NSCLC.
METHODS
We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of chemotherapy.
RESULTS
Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively).
CONCLUSION
The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients.

Keyword

Non-small cell lung cancer; Bone marrow; (18)F-Fluorodeoxyglucose positron emission tomography; Chemotherapy

MeSH Terms

Bone Marrow
Carcinoma, Non-Small-Cell Lung
Drug Therapy, Combination
Electrons
Humans
Liver
Logistic Models
Lumbar Vertebrae
Multivariate Analysis
Positron-Emission Tomography

Reference

1. Korea National Statistical Office. Deaths and death rate by cause. 2006. Daejeon: Korea National Statistical Office.

2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007. 57:43–66.

3. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000. 117:1247–1255.

4. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995. 311:899–909.

5. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol. 2004. 22:1966–1974.

6. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002. 20:23S–33S.

7. Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved? JAMA. 2004. 292:499.

8. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001. 19:1734–1742.

9. Sekine I, Tamura T, Kunitoh H, Kubota K, Shinkai T, Kamiya Y, et al. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol. 1999. 10:731–733.

10. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002. 359:1388–1393.

11. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004. 22:330–353.

12. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004. 44:317–325.

13. Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res. 2006. 12:4232–4236.

14. Ohtsuka T, Nomori H, Watanabe K, Kaji K, Naruke T, Suemasu K, et al. Prognostic significance of [¹⁸F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006. 107:2468–2473.

15. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [¹⁸F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005. 23:1136–1143.

16. Vansteenkiste JF, Stroobants SG, Dupont PJ, de Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro- 2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven lung cancer group. J Clin Oncol. 1999. 17:3201–3206.

17. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005. 130:151–159.

18. Prévost S, Boucher L, Larivée P, Boileau R, Bénard F. Bone marrow hypermetabolism on ¹⁸F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med. 2006. 47:559–565.

19. Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJ, et al. Monitoring response to therapy in cancer using [¹⁸F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000. 27:731–743.

20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst. 2000. 92:205–216.

21. Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer. 1996. 16:21–33.

22. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004. 10:5981–5987.

23. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007. 25:2747–2754.

24. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008. 59:377–384.

25. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006. 24:5034–5042.

26. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004. 350:2129–2139.

27. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001. 285:914–924.

28. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J. 1996. 9:410–414.

29. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004. 44:175–181.

30. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med. 2000. 343:254–261.

31. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000. 6:3837–3844.

32. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999. 40:1771–1777.

33. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995. 60:1348–1352.

34. Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, et al. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat. 2003. 78:97–103.

35. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003. 88:406–412.

36. Kimura H, Yamaguchi Y, Sun L, Iwagami S, Sugita K. Establishment of large cell lung cancer cell lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis. Jpn J Clin Oncol. 1992. 22:313–319.

37. Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001. 33:171–179.